The invention provides compounds represented by the formula:
wherein R1, R2, R3, R4, and n are as defined in the Summary of the Invention; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
The present invention provides compounds of the Formula I and II:
1
wherein R
1
, R
3
, W, Z, X
1
, X
2
, Ar
1
, R
8
and R
9
are as defined herein, and methods and intermediates for their preparation and uses thereof.
[EN] INHIBITORS OF AKT ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ D'AKT
申请人:MERCK SHARP & DOHME
公开号:WO2010088177A1
公开(公告)日:2010-08-05
The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.